Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-07 00:05 | 2025-11-04 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | Officer | OPT+S | $36.00 | 67,115 | $2,416,140 | 48,545 |
| 2025-11-07 01:01 | 2025-11-04 | QURE | uniQure N.V. | Kaye Jack | Director | OPT+S | $30.34 | 38,810 | $1,177,519 | 20,439 |
| 2025-11-07 00:40 | 2025-11-05 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $4.24 | 3,398 | $14,408 | 0 |
| 2025-11-06 16:01 | 2025-11-05 | NVCT | Nuvectis Pharma, Inc. | BENTSUR RON | Director, Officer, 10% owner | BUY | $5.72 | 5,000 | $28,600 | 3,525,924 |
| 2025-11-07 03:43 | 2025-11-04 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $1.22 | 155,885 | $189,837 | 3,787,474 |
| 2025-11-07 03:40 | 2025-11-04 | HOWL | Werewolf Therapeutics, Inc. | GADICKE ANSBERT | 10% owner | SELL | $1.22 | 242,890 | $295,791 | 5,904,720 |
| 2025-11-07 00:33 | 2025-11-04 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $436.05 | 8,000 | $3,488,422 | 130 |
| 2025-11-07 01:46 | 2025-11-04 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $42.16 | 7,040 | $296,778 | 62,400 |
| 2025-11-06 00:00 | 2025-11-04 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $910.72 | 526 | $479,038 | 93,931,452 |
| 2025-11-06 02:17 | 2025-11-04 | TERN | Terns Pharmaceuticals, Inc. | Quigley Jill M. | Director | OPT+S | $18.00 | 24,520 | $441,360 | 0 |
| 2025-11-06 02:24 | 2025-11-03 | ARQT | Arcutis Biotherapeutics Inc. | Vairavan Latha | Officer | SELL | $24.72 | 88 | $2,175 | 64,927 |
| 2025-11-06 02:23 | 2025-11-03 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd | Director, Officer | SELL | $24.72 | 11,547 | $285,399 | 794,893 |
| 2025-11-06 02:24 | 2025-11-03 | ARQT | Arcutis Biotherapeutics Inc. | Welgus Howard G. | Director | SELL | $25.27 | 10,000 | $252,669 | 89,744 |
| 2025-11-06 02:23 | 2025-11-03 | ARQT | Arcutis Biotherapeutics Inc. | Matsuda Masaru | Officer | SELL | $24.72 | 7,208 | $178,156 | 154,026 |
| 2025-11-06 00:30 | 2025-11-03 | PHAT | Phathom Pharmaceuticals, Inc. | Breedlove Robert Charles | Officer | SELL | $13.51 | 524 | $7,079 | 47,407 |
| 2025-11-06 02:57 | 2025-11-03 | ARQT | Arcutis Biotherapeutics Inc. | Burnett Patrick | Officer | SELL | $24.12 | 6,486 | $156,449 | 98,325 |
| 2025-11-06 01:00 | 2025-11-03 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Officer | OPT+S | $42.66 | 5,000 | $213,312 | 66,270 |
| 2025-11-06 05:15 | 2025-11-03 | SYRE | Spyre Therapeutics, Inc. | Turtle Cameron | Director, Officer | SELL | $23.33 | 45,000 | $1,049,778 | 701,907 |
| 2025-11-06 00:20 | 2025-11-03 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Officer | SELL | $25.72 | 5,931 | $152,565 | 7,195 |
| 2025-11-05 23:29 | 2025-11-04 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $4.40 | 3,102 | $13,634 | 0 |
| 2025-11-06 00:20 | 2025-11-03 | AMPH | Amphastar Pharmaceuticals Inc. | Petersen Floyd F. | Director | SELL | $25.27 | 500 | $12,633 | 75,531 |
| 2025-11-06 01:22 | 2025-11-03 | LGND | LIGAND PHARMACEUTICALS INC | KOZARICH JOHN W | Director | SELL | $191.05 | 467 | $89,219 | 44,588 |
| 2025-11-06 03:01 | 2025-11-03 | AXSM | Axsome Therapeutics, Inc. | TABUTEAU HERRIOT | Director, Officer, 10% owner | OPT+S | $133.07 | 163,939 | $21,815,674 | 7,229 |
| 2025-11-06 00:05 | 2025-11-04 | FOLD | AMICUS THERAPEUTICS, INC. | Clark David Michael | Officer | SELL | $9.51 | 25,643 | $243,860 | 322,618 |
| 2025-11-06 00:06 | 2025-11-03 | GALT | GALECTIN THERAPEUTICS INC | LEWIS JOEL | Director, Officer | OPT+S | $6.07 | 15,720 | $95,342 | 832,592 |
| 2025-11-06 00:06 | 2025-11-03 | GALT | GALECTIN THERAPEUTICS INC | CALLICUTT JACK W | Officer | OPT+S | $6.06 | 32,439 | $196,678 | 7,614 |
| 2025-11-06 02:00 | 2025-11-05 | BGMS | Bio Green Med Solution, Inc. | Yap Kim Choy | 10% owner | SELL | $1.70 | 28,540 | $48,518 | 0 |
| 2025-11-06 00:08 | 2025-11-03 | INSM | INSMED Inc | Smith Michael Alexander | Officer | OPT+S | $183.78 | 27,130 | $4,985,911 | 54,902 |
| 2025-11-06 03:59 | 2025-11-03 | CORT | CORCEPT THERAPEUTICS INC | Lyon Joseph Douglas | Officer | OPT+S | $73.65 | 5,000 | $368,245 | 10,277 |
| 2025-11-06 03:57 | 2025-11-03 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $74.58 | 40,000 | $2,983,120 | 2,741,370 |
| 2025-11-06 03:56 | 2025-11-03 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $73.99 | 20,000 | $1,479,816 | 7,904 |
| 2025-11-06 00:31 | 2025-11-04 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $436.09 | 21,000 | $9,157,821 | 8,118 |
| 2025-11-05 00:00 | 2025-11-03 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $888.83 | 300,000 | $266,648,910 | 93,931,978 |
| 2025-11-05 00:02 | 2025-11-03 | MRK | Merck & Co., Inc. | Williams David Michael | Officer | SELL | $83.59 | 8,614 | $720,040 | 24,578 |
| 2025-11-04 14:16 | 2025-10-31 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner | BUY | $9.26 | 2,300 | $21,298 | 5,572,902 |
| 2025-11-05 00:36 | 2025-10-31 | KNSA | Kiniksa Pharmaceuticals International, plc | Paolini John F. | Officer | OPT+S | $37.14 | 82,542 | $3,065,610 | 61,324 |
| 2025-11-05 00:13 | 2025-11-03 | ZLAB | Zai Lab Ltd | Chen Yajing | Officer | OPT+S | $26.83 | 240 | $6,439 | 17,444 |
| 2025-11-05 00:05 | 2025-10-31 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Officer | SELL | $35.00 | 5,591 | $195,685 | 119,071 |
| 2025-11-05 00:05 | 2025-10-31 | TVTX | Travere Therapeutics, Inc. | Coughlin Timothy | Director | OPT+S | $35.03 | 18,000 | $630,601 | 55,500 |
| 2025-11-05 00:30 | 2025-11-03 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $429.25 | 22,500 | $9,658,073 | 0 |
| 2025-11-05 00:31 | 2025-10-31 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $444.32 | 8,000 | $3,554,592 | 130 |
| 2025-11-05 03:23 | 2025-11-04 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $59.55 | 2,295 | $136,667 | 140,610 |
| 2025-11-04 00:00 | 2025-10-31 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $863.35 | 301,342 | $260,165,032 | 94,231,978 |
| 2025-11-04 00:30 | 2025-10-30 | RYTM | RHYTHM PHARMACEUTICALS, INC. | Shulman Joseph | Officer | OPT+S | $115.24 | 9,748 | $1,123,398 | 8,509 |
| 2025-11-04 03:08 | 2025-10-30 | HOWL | Werewolf Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 10% owner | SELL | $1.33 | 295,043 | $391,640 | 6,147,610 |
| 2025-11-04 03:14 | 2025-11-03 | NRIX | Nurix Therapeutics, Inc. | van Houte Hans | Officer | SELL | $12.56 | 6,284 | $78,931 | 37,592 |
| 2025-11-04 00:37 | 2025-11-03 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | OPT+S | $30.38 | 9,000 | $273,442 | 69,740 |
| 2025-11-04 04:14 | 2025-10-31 | IONS | IONIS PHARMACEUTICALS INC | Geary Richard S | Officer | OPT+S | $75.11 | 90,929 | $6,829,432 | 59,657 |
| 2025-11-04 00:10 | 2025-10-30 | AGIO | Agios Pharmaceuticals Inc. | Gheuens Sarah | Officer | OPT+S | $43.81 | 200 | $8,762 | 61,727 |
| 2025-11-04 00:46 | 2025-10-30 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Officer | SELL | $20.32 | 4,314 | $87,650 | 1,087,060 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.